Affymetrix (Santa Clara, California) (AFFX) Launches New OncoScan FFPE Assay Kit
8/5/2013 9:17:46 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ: AFFX) announced the launch of the new OncoScan™ FFPE Assay Kit, a whole-genome copy number assay for highly degraded FFPE solid tumor samples, at the Cancer Cytogenomics Microarray Consortium conference being held in Chicago this week. Despite the growing need of cancer researchers and clinicians, obtaining high-quality, whole-genome copy number data from degraded FFPE-derived tumor DNA has remained extremely challenging due to the limitations of current methods such as FISH, array CGH, and next-generation sequencing technologies.
Help employers find you! Check out all the jobs and post your resume.